References
- Makris M, Preston F E, Triger D R, et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990; 335: 117–1119
- Brettler D B, Alter H J, Dienstag J L, Forsberg A D, Levine P H. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1990; 76: 254–256
- Dienstag J L. Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology 1983; 85: 439–462
- Schvarcz R, Weiland O, Wejstal R, Norkrans G, Fryden A, Foberg U. A randomized controlled open study of interferon alpha-2B treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 1989; 21: 617–625
- David G L, Balart L A, Schiff E R, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–1506
- Marcellin P, Boyer N, Giostra E, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393–397
- Han J H, Shyamala V, Richman K H, et al. Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5′ untranslated region and poly (A) tails at the 3′ end. Proc Natl Acad Sci 1991; 88: 1711–1715
- Van der Poel C L, Cuypers H TM, Reesink H W, et al. Confirmation of hepatitis C virus infection by second generation four-antigen recombinant immunoblot assay and polymerase chain reaction. Lancet 1991; 337: 317–319